Literature DB >> 9220317

Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.

C J Kim1, T Prevette, J Cormier, W Overwijk, M Roden, N P Restifo, S A Rosenberg, F M Marincola.   

Abstract

Dendritic cells (DC) are potent professional antigen-presenting cells that can activate naive T lymphocytes and initiate cellular immune responses. As adjuvants, DC may be useful in enhancing the immunogenicity of tumor antigens and mediating tumor regression. Endogenous expression of antigen by DC offers the potential advantage of allowing prolonged constitutive presentation of endogenously processed epitopes and exploitation of multiple restriction elements for the presentation of the same antigen. In this report, we show that human DC are (a) capable of infection by recombinant poxviruses encoding melanoma-associated antigen (MAA) genes and (b) capable of efficiently processing and presenting these MAA to cytotoxic T cells. In 6/6 HLA A*0201-expressing melanoma patients tested, the virally driven expression of MART-1/Melan A MAA by DC was sufficient to generate CD8+ T lymphocytes that could recognize naturally processed epitopes on tumor cells. In most cases, specific anti-MART-1 reactivity could be detected after a single stimulation. Analysis of epitope dominance revealed that the amino acid sequence recognized by these cytotoxic T lymphocytes (CTL) corresponded to the MART-1(27-35) residues previously shown to be most commonly recognized by cytotoxic T lymphocytes expanded from metastatic melanoma lesions. These data show that the virally driven expression of MAA by DC can be exploited for the efficient induction of clinically relevant cytotoxic T-cell responses. This has clinical implications for active immunization therapy, and currently vaccine trials have been proposed for patients with metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9220317      PMCID: PMC2562268          DOI: 10.1097/00002371-199707000-00004

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  64 in total

1.  TNF and GM-CSF dependent growth of an early progenitor of dendritic Langerhans cells in human bone marrow.

Authors:  C D Reid; A Stackpoole; J Tikerpae
Journal:  Adv Exp Med Biol       Date:  1993       Impact factor: 2.622

2.  A new microcellular cytotoxicity test based on calcein AM release.

Authors:  X M Wang; P I Terasaki; G W Rankin; D Chia; H P Zhong; S Hardy
Journal:  Hum Immunol       Date:  1993-08       Impact factor: 2.850

3.  Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Authors:  Y Kawakami; S Eliyahu; C H Delgado; P F Robbins; L Rivoltini; S L Topalian; T Miki; S A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

4.  A nonimmunodominant nucleoprotein-derived peptide is presented by influenza A virus-infected H-2b cells.

Authors:  M Oukka; N Riché; K Kosmatopoulos
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

5.  Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells.

Authors:  M C Feltkamp; H L Smits; M P Vierboom; R P Minnaar; B M de Jongh; J W Drijfhout; J ter Schegget; C J Melief; W M Kast
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

Review 6.  Dendritic cell activity against primary tumors: an overview.

Authors:  Y Becker
Journal:  In Vivo       Date:  1993 May-Jun       Impact factor: 2.155

7.  Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.

Authors:  T Wölfel; A Van Pel; V Brichard; J Schneider; B Seliger; K H Meyer zum Büschenfelde; T Boon
Journal:  Eur J Immunol       Date:  1994-03       Impact factor: 5.532

8.  In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.

Authors:  J G Houbiers; H W Nijman; S H van der Burg; J W Drijfhout; P Kenemans; C J van de Velde; A Brand; F Momburg; W M Kast; C J Melief
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

9.  Role of dendritic cells in the priming of CD4+ T lymphocytes to peptide antigen in vivo.

Authors:  D Levin; S Constant; T Pasqualini; R Flavell; K Bottomly
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

10.  Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-04-01       Impact factor: 14.307

View more
  7 in total

1.  Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.

Authors:  S Gnjatic; Y Nagata; E Jager; E Stockert; S Shankara; B L Roberts; G P Mazzara; S Y Lee; P R Dunbar; B Dupont; V Cerundolo; G Ritter; Y T Chen; A Knuth; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 2.  Whole tumor antigen vaccines.

Authors:  Cheryl Lai-Lai Chiang; Fabian Benencia; George Coukos
Journal:  Semin Immunol       Date:  2010-03-30       Impact factor: 11.130

3.  Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.

Authors:  Yu-gang Wu; Guang-zhou Wu; Liang Wang; Yan-Yun Zhang; Zhong Li; De-Chun Li
Journal:  Med Oncol       Date:  2009-08-08       Impact factor: 3.064

4.  An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens.

Authors:  Bei Wang; Jin He; Chen Liu; Lung-Ji Chang
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

5.  Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells.

Authors:  D Nagorsen; M Panelli; M E Dudley; S E Finkelstein; S A Rosenberg; F M Marincola
Journal:  Gene Ther       Date:  2003-09       Impact factor: 5.250

6.  Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.

Authors:  N P Restifo; D R Surman; H Zheng; P Palese; S A Rosenberg; A García-Sastre
Journal:  Virology       Date:  1998-09-15       Impact factor: 3.616

7.  Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells.

Authors:  Fabian Benencia; Maria C Courrèges; George Coukos
Journal:  J Transl Med       Date:  2008-04-29       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.